Sonia Garcia

If you're reading this, someone may have just mentioned the word "hospital." Maybe a doctor suggested it for you, or your family is weighing it for someone you love. Movies have made psych wards and mental hospitals sound frightening and permanent. In reality, most psychiatric hospital stays today are short, focused on safety and stabilization, and followed by care at home.

So what's the difference? A psych ward is the everyday name for an inpatient psychiatric unit inside a general hospital. A mental hospital, more formally a psychiatric hospital, is a facility devoted entirely to psychiatric care. Both provide the same basic thing: 24-hour treatment for someone who isn't safe or stable enough to be treated at home right now.

What is a psych ward?

A psych ward, also called a psychiatric unit or behavioral health unit, is a locked or secured floor of a general hospital. People are often admitted after an emergency department visit. Because it sits inside a medical hospital, the unit has quick access to other specialists, which matters when someone also has a medical problem, such as an overdose, a physical illness, or a medication reaction.

The goal is stabilization: keeping the person safe, starting or adjusting treatment, and building a plan for what happens after discharge.

What is a mental hospital?

A mental hospital is a standalone psychiatric hospital. Some are private, some are run by states, and some specialize in groups such as adolescents or older adults. Older terms like "mental institution" and "asylum" come from an era of long-term confinement that looks very different from psychiatric care today.

Many psychiatric hospitals offer short-term crisis care much like a hospital unit. Some also provide other services on the same campus, including partial hospitalization or outpatient programs for people stepping down from inpatient care.

Psych ward vs. mental hospital: the key differences

The differences are mostly about setting, not about the kind of care:

• Location. A psych ward is one unit in a general hospital. A mental hospital is its own facility.
• Medical backup. A general hospital unit has full medical services down the hall. A freestanding psychiatric hospital may transfer patients for complex medical care.
• Range of programs. Psychiatric hospitals more often run specialized units and step-down programs. A hospital psych unit usually focuses on acute care alone.
• Who goes where. It often depends less on the person than on geography, insurance, and which facility has an open bed.

In both settings, the treatment team typically includes psychiatrists, nurses, social workers, and therapists, and the core of care is the same.

What happens in a psych ward or mental hospital?

A stay usually follows a similar pattern:

• Evaluation. A psychiatrist assesses symptoms, safety, history, and medications soon after admission. Medical tests may rule out physical causes.
• Safety. Units remove items that could be used for self-harm, and staff check on patients regularly. Belongings, phones, and visiting hours are usually restricted.
• Treatment. Medication is started or adjusted, and most units run group sessions on coping skills, symptoms, and planning for discharge.
• Discharge planning. From day one, the team works on where the person will go next and who will see them after they leave.

Policies vary by facility, so it's reasonable to call the unit and ask what to bring and how visiting works.

How long do people stay?

Usually days, not months. A federal analysis of U.S. hospital data found that in 2016, hospital stays principally for mental and substance use disorders lasted 6.4 days on average. Stays for schizophrenia averaged about 11 days, and eating disorders, the longest, about 14 days.

A short stay is enough to get someone through a crisis. It is rarely enough to finish treatment, which is why the plan after discharge matters so much.

Voluntary and involuntary admission

Many people are admitted voluntarily. Involuntary admission, sometimes called an emergency hold or civil commitment, is generally used when someone is judged to be a danger to themselves or others, or unable to care for themselves because of a mental illness, and won't accept care voluntarily.

The rules are set by each state, and they differ a lot. A 2021 study in Psychiatric Services that compiled data from 25 states found that rates of emergency involuntary detention varied 33-fold, from 29 per 100,000 people in Connecticut to 966 in Florida. If you're facing this for a family member, the hospital's social worker or patient advocate can explain how the process and patient rights work in your state.

Who needs inpatient psychiatric care?

Hospitalization is for moments when someone can't be kept safe or treated effectively outside a hospital. Common reasons include:

• Suicidal thoughts with a plan or intent, or a recent suicide attempt (see our page on care for suicidal thoughts)
• Psychosis that makes it unsafe to stay at home
• Severe mania
• Severe depression that has stopped someone from eating, sleeping, or caring for themselves

People often ask whether anxiety can lead to a hospital stay. We've covered that in can you be hospitalized for anxiety.

If you or someone you love is in danger right now, call or text 988, the Suicide & Crisis Lifeline, or call 911.

What happens after discharge

The weeks after leaving the hospital are a vulnerable stretch. A 2017 meta-analysis in JAMA Psychiatry of 100 studies found that suicide rates after psychiatric discharge were highest in the first three months, especially for people admitted with suicidal thoughts or behaviors. That isn't a reason to avoid the hospital. It's a reason to make sure care doesn't stop at the door.

For many people, the next step is a structured program that's less intensive than a hospital but far more than a weekly appointment:

• A Partial Hospitalization Program (PHP) provides treatment for most of the day, several days a week, while the person sleeps at home.
• An Intensive Outpatient Program (IOP) offers several hours of treatment a few days a week, often while someone returns to work or school.

For a side-by-side comparison, see PHP vs. IOP.

Where Amae Health fits

We aren't a hospital. Amae Health runs outpatient clinics for adults living with severe mental illness (SMI), including schizophrenia, bipolar disorder, and Major Depressive Disorder, with PHP and IOP programs for people who need more than weekly care. Our care teams bring psychiatrists, therapists, primary care physicians, peer mentors, and care coordinators under one roof, working from one treatment plan.

That makes our programs a natural next step after a hospital stay, and an option for people who need more support than weekly appointments but don't need a hospital.

Frequently asked questions

What is a psych ward?

A psych ward is an inpatient psychiatric unit, usually inside a general hospital, that provides 24-hour care for people in a mental health crisis. Stays focus on safety, stabilization, and planning for treatment after discharge.

Is a psych ward the same as a mental hospital?

Not exactly. A psych ward is a unit within a general hospital, while a mental hospital is a standalone psychiatric facility. The core care, stabilization with medication, therapy, and discharge planning, is similar in both.

How long do you stay in a psych ward?

Most stays last days to about two weeks. In U.S. hospital data from 2016, stays for mental and substance use disorders averaged 6.4 days.

Can you leave a psych ward if you want to?

If you were admitted voluntarily, you can usually request discharge, though the process and timing depend on the facility and state law. If you were admitted involuntarily, release depends on your state's legal process.

What comes after a psych ward?

Usually a step-down program such as partial hospitalization or intensive outpatient treatment, plus follow-up with a psychiatrist and therapist. The first weeks after discharge are when continued care matters most.

Key takeaways

• A psych ward is a psychiatric unit in a general hospital. A mental hospital is a standalone psychiatric facility. Both provide short-term, 24-hour care.
• Most stays last days, not months, with an average of 6.4 days in recent U.S. data.
• Admission rules, especially for involuntary holds, are set by each state.
• The weeks after discharge carry the highest risk, so a solid step-down plan, such as PHP or IOP, matters as much as the stay itself.

If you or a loved one is leaving the hospital, or trying to get enough support to avoid going back, request an intake appointment. Our team will explain what PHP and IOP involve, what a first visit looks like, and what to bring, including any discharge paperwork.

Maybe a genetic report flagged it. Maybe a friend, a forum, or a supplement ad told you it could explain your fatigue, your depression, or why medication never quite worked. Now you're wondering what an MTHFR gene mutation actually means for you.

MTHFR variants are extremely common. Most people who carry them have no health effects at all, and research linking them to mental health conditions shows a real but small association, not a cause. Medical experts don't recommend routine testing for them.

What the MTHFR gene does

The MTHFR gene carries instructions for an enzyme called methylenetetrahydrofolate reductase. That enzyme converts folate, a B vitamin, into the active form your body uses to turn the amino acid homocysteine into methionine. According to MedlinePlus Genetics, the active form, 5-methyltetrahydrofolate, is the main form of folate found in blood.

When the enzyme works less efficiently, homocysteine can build up. That's the mechanism behind most of the interest in MTHFR, including the mental health questions.

C677T, A1298C, heterozygous, and homozygous

Most people searching "MTHFR gene mutation" are really asking about two common variants:

• C677T. The most common and best studied. At position 677 in the gene, the DNA base C is replaced by T. The resulting enzyme is less stable and less active, especially in people with two copies.
• A1298C. The second common variant. The CDC notes there isn't enough evidence that A1298C on its own significantly affects how the body processes folate.

You inherit one copy of the gene from each parent, which is where the lab terms come from:

• Heterozygous means one copy carries the variant (for C677T, written CT).
• Homozygous means both copies carry it (TT).
• Compound heterozygous means one copy of C677T and one copy of A1298C.

These variants are so common they're closer to normal human variation than to a disease. The CDC reports that more people in the U.S. have one or two copies of C677T than don't. Having both copies is less common: MedlinePlus estimates about 25% of Hispanic people and 10% to 15% of North American white people carry two copies of C677T.

MTHFR symptoms: what the variant does and doesn't cause

Most people with common MTHFR variants have no symptoms. Cleveland Clinic puts it plainly: MTHFR gene variants most often don't affect your health or cause symptoms. When they do matter, it's usually through higher homocysteine or lower folate, and mostly in people with two copies of C677T. Even then, how much folate you get from food matters more than your genotype.

That's different from what you'll read on many wellness sites, which attribute everything from fatigue to brain fog to MTHFR. There's no reliable evidence for a list of "MTHFR symptoms" in people with the common variants. If you have symptoms, they deserve an evaluation, not an assumption that a gene variant explains them.

There is one important exception. Rare, severe mutations in the MTHFR gene cause homocystinuria, a serious inherited condition whose symptoms usually appear early in life. Most U.S. newborns are screened for it shortly after birth. That's a different situation from the common C677T and A1298C variants.

MTHFR and mental health: what research shows

Because MTHFR sits in the folate and methylation pathway, researchers have looked hard for links to psychiatric conditions. The findings are consistent in one way: the effect is modest.

• Depression. A 2013 meta-analysis of 26 studies, with 4,992 people with depression and 17,082 controls, found that two copies of C677T were associated with higher odds of depression (odds ratio 1.42). The link was stronger in Asian populations, marginal in white populations, and absent in older adults.
• Schizophrenia, bipolar disorder, and depression combined. A 2011 meta-analysis of case-control studies with 29,502 participants found TT carriers had modestly higher odds of these conditions as a group (odds ratio 1.26). The authors read this as evidence of a shared genetic vulnerability across the three conditions.

An odds ratio of 1.26 to 1.42 is a small increase in relative risk for a very common genotype. Most people with two copies of C677T never develop depression, bipolar disorder, or schizophrenia, and most people with those conditions don't have two copies. Mental health conditions come from many genes and life experiences acting together. MTHFR is, at most, one small piece.

Folate, folic acid, and methylfolate

A common online claim is that people with MTHFR variants can't use folic acid and need "methylated" supplements instead. The CDC says that isn't true: people with an MTHFR variant can process all types of folate, including folic acid. People with the TT genotype have blood folate levels only about 16% lower on average than people with CC at the same intake, and folic acid intake matters more than genotype in determining blood folate.

L-methylfolate, the active form, has been studied as an add-on to antidepressants. In two randomized trials published in the American Journal of Psychiatry in 2012, adults with depression that hadn't responded fully to an SSRI received L-methylfolate or placebo alongside their medication. The first trial, with 148 patients starting at 7.5 mg a day, found no difference. The second, with 75 patients at 15 mg a day, found a significant benefit over placebo. Both enrolled people based on their depression, not on a genetic test. Whether any add-on makes sense for a specific person is a clinical decision that depends on their full history.

For more on how folate and other nutrients relate to mood, see our article on nutrient deficiencies and anxiety.

Should you get tested for MTHFR?

For most people, no. MedlinePlus states that medical experts don't recommend testing for common MTHFR gene changes in most cases. A provider may order it in specific situations, such as high homocysteine on a blood test combined with a family history.

The American College of Medical Genetics and Genomics went further in a 2013 practice guideline: MTHFR polymorphism testing has minimal clinical utility and shouldn't be part of a routine evaluation for blood clotting disorders. Recent meta-analyses had disproven the links that originally motivated the testing.

If you already have a result, it's still useful context to share with your care team. It just isn't a diagnosis, and it isn't a treatment plan.

When depression or mood symptoms don't improve

People often look up MTHFR because something isn't working: depression that keeps coming back, medication that only half helps, or mood swings no one has explained. Those problems are real, even if MTHFR is unlikely to be the answer. They usually call for a fuller psychiatric evaluation: a closer look at the diagnosis, past medication trials, co-occurring conditions, sleep, substance use, and physical health.

That's the kind of care we provide at Amae Health. Our clinics specialize in conditions including Major Depressive Disorder, bipolar disorder, and schizophrenia. Our care teams bring psychiatrists, therapists, primary care physicians, and dietitians under one roof, so lab results, nutrition, and medication history are reviewed together, by people who share one treatment plan. See how our integrated outpatient clinics work.

Frequently asked questions

How common is the MTHFR gene mutation?

Very common. According to the CDC, more people in the U.S. have one or two copies of the C677T variant than don't. Two copies are less common, estimated at about 25% of Hispanic people and 10% to 15% of North American white people.

What are the symptoms of being MTHFR C677T heterozygous?

Usually none. According to MedlinePlus, raised homocysteine is seen mainly in people with two copies of C677T. If you have symptoms, they need an evaluation of their own rather than being attributed to one copy of a common variant.

Does MTHFR cause depression?

No single gene causes depression. Two copies of C677T are associated with modestly higher odds of depression in meta-analyses, with an odds ratio around 1.4, but most people who carry them never develop depression.

Do people with MTHFR need methylfolate instead of folic acid?

According to the CDC, no. People with MTHFR variants can process folic acid, and folic acid intake matters more than genotype for blood folate levels. L-methylfolate has been studied as an add-on treatment for depression, regardless of MTHFR status, and decisions about it belong with a clinician.

Is MTHFR testing worth it?

For most people, it isn't recommended. Medical genetics experts say the common variants have minimal clinical utility. A provider may order testing in specific cases, such as unexplained high homocysteine with a family history.

Key takeaways

• An MTHFR gene mutation usually means one or two copies of the common C677T or A1298C variants, which most people carry without health effects.
• Two copies of C677T can raise homocysteine and are linked to modestly higher odds of depression, bipolar disorder, and schizophrenia, but the effect is small.
• People with MTHFR variants can process folic acid, and routine MTHFR testing isn't recommended.
• If depression or mood symptoms aren't improving, a full psychiatric evaluation is more useful than a gene result.

If you or someone you love is living with depression, bipolar disorder, or schizophrenia that hasn't responded to treatment, request an intake appointment. Our team will walk you through how an evaluation works and what to bring, including any lab or genetic results you already have.

Comparing Spravato vs ketamine infusion treatment means comparing two versions of the same idea: using ketamine's fast action on the brain's glutamate system to treat depression that standard antidepressants haven't relieved. The best comparison so far, a 2025 meta-analysis by Mayo Clinic researchers, found no statistically significant difference in how often the two lead to response or remission. What separates them is everything around the drug: FDA status, how it's given, how quickly it tends to work, what it costs, and who pays.

‍

So far, neither has been shown to be the better drug.

What Is Spravato (Esketamine)?

Esketamine vs ketamine comes down to chemistry. Standard ketamine is an equal mix of two mirror-image forms of the same molecule. Esketamine is one of those forms on its own, and Spravato is esketamine delivered as a nasal spray.

‍

The FDA first approved Spravato in 2019 for treatment-resistant depression, taken together with an oral antidepressant, as the Mayo Clinic review notes. A second approval, again paired with an oral antidepressant, covers depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behavior. And the most recent change came in January 2025, when the FDA added standalone use for treatment-resistant depression, as the current prescribing information shows.

‍

Every dose happens in a certified healthcare setting under the Spravato REMS, an FDA-required safety program. Each device delivers 28 mg, and a session uses two or three devices (56 or 84 mg), with a five-minute wait after each one. You're then monitored for at least two hours, and you can't drive again until the next day, once you've had a restful night's sleep. The label sets the early schedule: twice a week for weeks one through four, once a week for weeks five through eight, then weekly or every two weeks, adjusted to the least frequent dosing that maintains the response.

What Is Ketamine Infusion Therapy?

A ketamine infusion uses standard ketamine, both mirror-image forms together, delivered through an IV line. Ketamine has been FDA-approved as an anesthetic since 1970, but for depression, IV ketamine "remains an off-label treatment," in the Mayo Clinic review's words. Off-label prescribing is legal and common in medicine. It also means there is no FDA-approved depression regimen, so dosing schedules and safety protocols are set by each clinic.

‍

The most studied dose is 0.5 mg per kilogram of body weight, infused over about 40 minutes with continuous heart and blood pressure monitoring. A first course typically runs two to three infusions a week for about three to six treatments, followed by maintenance sessions on a schedule that varies from clinic to clinic.

Spravato vs Ketamine Infusion: Side-by-Side Comparison

Efficacy: What the Research Shows

The most complete head-to-head evidence is the 2025 Mayo Clinic meta-analysis in Therapeutic Advances in Psychopharmacology. The authors identified eight studies with 978 patients in total. Only one was a randomized trial, and it compared IV ketamine with an IV form of esketamine rather than the nasal spray, so the pooled comparison rests on observational studies of IV ketamine versus nasal esketamine.

‍

In those studies, the odds of response were 1.26 times higher with IV ketamine and the odds of remission 1.31 times higher, but neither difference was statistically significant. The authors concluded that the evidence suggests no significant difference in short-term efficacy, with a slight numerical trend favoring IV ketamine.

‍

Speed may be where the two differ. In one Mayo Clinic observational study included in the review, people reached remission after a median of two IV ketamine treatments, compared with seven nasal esketamine treatments. That's a real gap in lived experience. But it comes from observational data, where the people who choose or can access each treatment may differ in ways a study can't fully account for.

‍

So is Spravato better than ketamine infusions? On current evidence, neither has been shown to be. A randomized trial built to settle the question, called EQUIVALENCE, plans to assign 400 people to one treatment or the other for eight sessions over four weeks. Its protocol was published in 2026, and results are not yet available.

FDA Approval and Insurance Coverage

FDA approval changes who pays. Because Spravato has approved indications, insurers can write coverage criteria around it, and they typically require prior authorization and documentation of earlier antidepressant trials. Ketamine infusions for depression are off-label, so coverage is inconsistent, and many people pay out of pocket.

‍

The Spravato vs ketamine cost comparison has a twist. Economic modeling cited in the Mayo Clinic review found nasal esketamine unlikely to be cost-effective compared with IV ketamine from a health-system perspective. Yet an individual patient's out-of-pocket cost for Spravato may be lower, thanks to insurance coverage or manufacturer assistance. Published price estimates vary too widely by dose, frequency, and coverage to quote a single figure, so ask each provider and your insurer for the numbers that apply to you.

Side Effects and Safety Considerations

Because both drugs act on the same receptor, their side effects overlap. In Spravato's clinical trials, 48% to 61% of people developed sedation, and 61% to 84% experienced dissociative or perceptual changes, such as distortions of time or space, according to the prescribing information. Dizziness, nausea, vertigo, anxiety, and a temporary rise in blood pressure are also common, which is why blood pressure is rechecked about 40 minutes after dosing. IV ketamine produces the same family of effects, concentrated during and shortly after the infusion.

‍

Direct safety comparisons are limited. In one retrospective analysis included in the Mayo Clinic review, a rise in blood pressure during treatment occurred in 45% of IV ketamine patients versus 9.2% of nasal esketamine patients, and dissociative effects were also more frequent with IV ketamine, though they were described as transient. That is one retrospective study. It doesn't establish either drug as safer overall.

‍

Both drugs carry a potential for misuse, which shapes who is a candidate, and each has its own exclusions. Spravato, for example, isn't used in people with aneurysmal blood vessel disease, an arteriovenous malformation, or a history of bleeding in the brain.

What Influences the Choice Between Them

There isn't a universal right answer. A psychiatrist weighing the two usually considers:

‍

• Coverage and cost. Whether insurance will cover Spravato in your situation, and whether infusions are affordable out of pocket.
• How quickly relief is needed. Early data suggest infusions may reach remission in fewer sessions, which matters more when symptoms are severe.
• Medical history. Blood pressure, vascular conditions, and any history of substance misuse.
• Route. Some people would rather avoid an IV line. Others prefer an infusion that can be slowed or stopped.
• Logistics. Spravato means at least two hours in the clinic and no driving until the next day, twice a week at first. Infusions take about 40 minutes, plus recovery time that varies by clinic.
• Continuity. Whether you're already established with a psychiatrist or clinic that offers one of them.

‍

The choice belongs in a conversation with a psychiatrist who knows your treatment history, not in a ranking of favorites.

Making the Decision With a Psychiatrist

Spravato and ketamine infusions are tools for treatment-resistant depression, not a complete plan. They work alongside medication, therapy, and ongoing psychiatric care, and they sit among other options, including TMS therapy for depression that hasn't responded to medication. When depression brings thoughts of suicide, care for suicidal thoughts comes first.

‍

We don't offer Spravato at Amae. Our psychiatrists treat depression that hasn't responded to medication through our integrated care model, with therapy, medication management, and TMS, which we provide in Los Altos, San Mateo, and Los Angeles. Whether the question is Spravato vs ketamine infusion or something else entirely, talk through your options with an Amae psychiatrist, including ones we don't provide ourselves. For anyone in crisis right now, 988 is a call or text away.

Frequently Asked Questions

Is Spravato more effective than ketamine infusions?

Not on current evidence. A 2025 meta-analysis found no statistically significant difference in response or remission between IV ketamine and nasal esketamine, only a slight numerical trend favoring IV ketamine. Most of that evidence is observational, and a large randomized head-to-head trial is still underway.

Which works faster, Spravato or ketamine infusions?

IV ketamine may reach remission in fewer sessions. In one observational study, the median was two IV infusions versus seven nasal esketamine treatments. Because that finding comes from observational data rather than a randomized trial, treat it as preliminary.

Is Spravato safer than ketamine infusions?

Neither has been established as safer overall. The two share a similar side-effect profile because they act on the same receptor. One retrospective comparison found more blood pressure spikes and dissociation with IV ketamine, but a single study can't settle the question, and individual risk depends on your medical history.

Why is Spravato covered by insurance but ketamine infusions often aren't?

Spravato has FDA approval for treatment-resistant depression, which gives insurers defined criteria for covering it, usually with prior authorization. IV ketamine for depression is off-label, so coverage is inconsistent and infusions are often self-pay.

Can I switch between Spravato and ketamine infusions?

That's a clinical decision to make with a psychiatrist, based on how you've responded, the side effects you've had, your goals, and your coverage. It isn't something to change on your own.

How many sessions does each treatment typically require?

Spravato starts at twice a week for four weeks, then weekly, then weekly or every two weeks based on response. Ketamine infusions often begin with three to six sessions given two to three times a week, followed by maintenance on a schedule that varies by clinic.

‍

Citations

1. Elmosalamy A, Tarikogullari I, Patarroyo-Rodriguez L, et al. Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis. Therapeutic Advances in Psychopharmacology. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12615959/ (Tier 1)
2. U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray prescribing information, revised January 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf (Tier 2)
3. Wilkinson ST, Prashad S, Dalthorp R, et al. Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: the EQUIVALENCE trial protocol. Contemporary Clinical Trials. 2026;164:108273. https://pubmed.ncbi.nlm.nih.gov/41780747/ (Tier 1, trial protocol)
4. 988 Suicide and Crisis Lifeline. https://988lifeline.org (Tier 2)

‍